Thomas Dayspring: A Decade on Repatha – Stable CAD, No Ischemic Events
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Anecdotal Study of 1 — Me — I have chronic stable CAD (CAC > 300 15 years ago). With that and other risk factors I had, I easily would have qualified for inclusion in the VESALIUS CV Trial. Fortunately, as soon as PCSK9i came on the market I went on Repatha and now a decade later I am still here – no ischemic events. The day after I got the CAC, I had an invasive coronary angiogram which demonstrated wide open lumens: disease was all in arterial wall. Here is data from GLACOV that shows evolocumab not only kept me alive without any CV issues but likely is causing regression. My apoB on Repatha monotherapy is 50 mg/dL and LDL-C 45 mg/dL. THANK YOU REPATHA, Amgen National Lipid Association European Atherosclerosis Society, American Society for Preventive Cardiology (ASPC).”
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO
-
Dec 16, 2025, 00:32New on EHCucate: Read about the “History of Replacement Factor Therapies” and More